ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Botulinum Toxin Injections for ADSD and Chronic Salivary Aspiration

by Arevalo, Jennifer Decker MA • December 1, 2007

  • Tweet
  • Email
Print-Friendly Version

Presenters at several scientific sessions at the Combined Otolaryngology Spring Meeting (COSM) reported on their recent studies involving the use of botulinum toxin type A (Botox® [BTX]; Allergan, Inc., Irvine, CA) injections to treat adductor spasmodic dysphonia (ADSD) and chronic salivary aspiration.

You Might Also Like

  • Two Techniques Compared for Laryngeal Botulinum Toxin Injection
  • Intraductal Botulinum Toxin Is Safe for Managing Salivary Disorders
  • Long-Term Botulinum Toxin Management of OMD
  • Does Intraglandular Injection of Botulinum Toxin Improve Pediatric Sialorrhea?
Explore This Issue
December 2007

Botulinum toxin is produced by the bacterium Clostridium botulinum and achieves an irreversible neuromuscular blockade at presynaptic terminals, preventing the release of acetylcholine in response to action potentials.1 BTX cleaves to the SNARE protein, SNAP-25 (integral to the docking/release of acetylcholine vesicles at nerve endings), resulting in flaccid paralysis within a day or two that lasts for approximately three to four months.

During the past two decades, BTX therapy has been increasingly used to treat otolaryngological disorders of excessive or inappropriate muscle contraction before pursuing surgical options. These disorders include:

  • Spasmodic dysphonia (adductor or abductor);
  • Complex dystonias (oromandibular, laryngeal, cervical);
  • Facial hyperkinesias (blepharospasms, hemifacial spasm);
  • Vocal tics and stuttering;
  • Cricopharyngeal achalasia;
  • Various tremors and tics;
  • Laryngeal granulomas;
  • Posterior glottic synechiae;
  • Gustatory sweating;
  • Hypersalivation;
  • Temporomandibular joint disorders; and
  • Certain cosmetic applications.2,3,4

ADSD

Today, BTX injection is considered the gold standard treatment for ADSD, the most common clinical type of spasmodic dysphonia, in which there is increased activity of the vocal fold adductors, characterized by strained and strangled speech with breaks in pitch and phonation. The American Academy of Otolaryngology-Head and Neck Surgery has endorsed BTX injection for spasmodic dysphonia.

A patient with ADSD will feel the clinical effects of a laryngeal BTX injection into the thyroarytenoid (TA) muscle within 24 to 48 hours, but may experience breathiness and occasionally dysphagia for one to two weeks afterward. Symptoms will improve for a period of about two to five months, until new nerve terminals sprout and the muscle returns to its preinjection state and the cycle begins again. Because the effect is temporary, a patient is faced with the lifelong prospect of undergoing an injection procedure every three to four months. There is some concern that repeated injections may cause resistance or irreversible denervation to develop. The dose required for treatment varies due to the accuracy of injection, severity of ADSD, and sensitivity of the patient’s larynx to BTX.5

Dose Stability

Because there are few data regarding the long-term dose stability and consistency of BTX in the treatment of ADSD, researchers at the University of California, Irvine, Medical Center conducted a retrospective review of 13 subjects who had received a minimum of six injections (average = 11.5, range 6-19), to establish a baseline set of data to back the widely held belief that BTX dosing is stable in the treatment of ADSD.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Laryngology Issue: December 2007

You Might Also Like:

  • Two Techniques Compared for Laryngeal Botulinum Toxin Injection
  • Intraductal Botulinum Toxin Is Safe for Managing Salivary Disorders
  • Long-Term Botulinum Toxin Management of OMD
  • Does Intraglandular Injection of Botulinum Toxin Improve Pediatric Sialorrhea?

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.